drugset
drugset / Trial / NCT01056679

Adriamycin, Vinblastine, DTIC and Revlimid in Elderly Hodgkin Lymphoma Patients

NCT01056679 ↗

Phase 1 Completed 30 enrolled University of Cologne
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine within the scope of the trial what the maximum tolerated dose (MTD) of lenalidomide in combination with AVD should be.

Timeline

Start
2010-04
Primary completion
2014-04
Completion
2016-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Lenalidomide Other / unclassified — —
Background Dacarbazine Small molecule 375 mg/m2 —
Background Doxorubicin Other / unclassified 50 mg/m2 —
Background Vinblastine Small molecule 6 mg/m2 —

Indications

Hodgkins lymphoma